Access to lifesaving epinephrine drug is a focus of law that began its journey before COVID-19 focus.
Florida Gov. DeSantis’ executive order seen as example of removing barriers that otherwise could prevent patients from maintaining access to needed medications
NACDS and the American Pharmacists Association (APhA) expressed concerns about the risks to patient health and the security of the prescription drug supply chain in opposing legislation that would allow for personal and commercial importation of prescription drugs outside of the Food and Drug Administration’s (FDA) oversight.
NACDS applauded the Trump Administration’s focus on reducing patients’ out-of-pocket drug costs, and Congressional sponsors’ effectiveness in advancing the "gag clause" ban. NACDS noted that pharmacy is a long-standing and trusted partner in helping patients achieve prescription-drug affordability – which is essential for health and wellness.
NACDS updated chain members on the Trump Administration's announcement regarding prescription drug pricing policies, and indicated events over the next several days expected to provide more details.
Morning Consult published an op-ed co-authored by Steven C. Anderson, IOM, CAE, president and CEO of NACDS, and Gigi Kwik Gronvall, PhD., senior associate at the Johns Hopkins Center for Health Security.
The Supreme Court ruled unanimously this week in a decision on biosimilar medications, a ruling that could save patients and the healthcare system billions of dollars.
This week, NACDS and pharmacists from H-E-B and The Kroger Co. met with Rep. John Frullo (R) to thank him for his leadership on HB 1296, the medication synchronization bill that passed the House in Texas and is pending in the Senate.
NACDS President & CEO Steven C. Anderson participated in a listening session at the invitation of Health and Human Services Secretary Tom Price.
A joint op-ed by NACDS and the Healthcare Distribution Alliance (HDA) was published in The Hill on the inherent risks of importing drugs from foreign markets.
